Alliance Pharmaceuticals (APH)

Executive Summary

Alliance Pharmaceuticals is a UK-based consumer healthcare company focused on building a portfolio of trusted, proven brands in pain relief, skincare, and digestive health. With 8 commercial products and a strong international presence, the company has demonstrated consistent revenue growth driven by brand equity and strategic distribution partnerships. In recent years, Alliance has shifted towards a higher-margin consumer health portfolio, divesting some prescription assets to sharpen focus. The company's valuation of ~£184 billion (based on market cap) reflects its stable cash flows and growth prospects in the OTC market. However, near-term growth faces headwinds from generic competition in key markets and currency volatility. Management's strategy involves targeted acquisitions and geographic expansion, particularly in Asia-Pacific and Latin America, to offset mature market pressures. With a robust balance sheet and disciplined capital allocation, Alliance is well-positioned to deliver moderate but reliable returns. The conviction score of 65 reflects a balanced risk-reward profile.

Upcoming Catalysts (preview)

• Q1 2027Launch of new pain relief gel in the US market60% success
• Q4 2026Completion of acquisition of a complementary dermatology brand50% success
• Q3 2026Half-year 2026 earnings release and strategic update100% success